Exclusive Summary

• Best-in-class Potential: UB705 is an innovative long-acting PTH peptide conjugate featuring a once-weekly (QW) subcutaneous regimen, drastically enhancing patient treatment compliance compared to the marketed daily (QD) counterparts.
• Overwhelming Preclinical Superiority: In hypoparathyroidism rat models, an ultralow dose of UB705 (3 nmol/kg) steadily maintained physiological blood calcium levels for a full 7 days without significant peak-and-trough fluctuations, vastly outperforming its Phase II rival pipeline drug MBX-2109.
• Highly Attractive Orphan Asset for Out-Licensing: Addressing critical unmet clinical needs globally, this IND-enabling stage candidate demonstrates formidable differentiation barriers, making it a lucrative and de-risked focal target for oversea pharma companies looking to aggressively expand their endocrine and rare disease portfolios.

Asset Materials

Contact Us for Full Materials